# Judy E. Garber

Source: https://onco.cc/people/judy-garber/  
OnCo record `judy-garber` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A leading authority on inherited cancer risk and how BRCA carriers should be treated and screened.

## Summary

Judy E. Garber is Chief of the Division of Cancer Genetics and Prevention and holds the Susan F. Smith Chair at Dana-Farber Brigham Cancer Center. She is a leading authority on inherited cancer risk and on how BRCA carriers should be treated and screened, having contributed to the TBCRC neoadjuvant cisplatin trials in BRCA-associated breast cancer and to the OlympiA trial. Her selected paper reports adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. She directs cancer genetics and prevention at Dana-Farber, spanning germline testing, chemoprevention and risk-reducing surgery.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief, Division of Cancer Genetics and Prevention; Susan F. Smith Chair
- Specialisms: Hereditary cancer; BRCA1/2; Cancer prevention

## Sources

- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/judy-e-garber
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [OlympiA](https://onco.cc/trials/olympia/)
- key papers: [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer](https://onco.cc/key-papers/paper-olympia-overall-survival-ann-oncol-2022/), [Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial](https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- people: [Angelina Jolie](https://onco.cc/people/angelina-jolie/), [Mary-Claire King](https://onco.cc/people/mary-claire-king/)

---
JSON: https://onco.cc/api/v1/entities/judy-garber.json